Introduction
Osteomyelitis is an inflammatory response of bone marrow, cortex, and periosteum caused by bacterial infection.
1,2 The current approach for treating osteomyelitis is mainly clinical surgery with the aid of high-dose antibiotics, which may cause antibiotic resistance and intense pain for the patients physically and mentally. [3] [4] [5] Therefore, there is an urgent need to develop injectable nano-and/or micro-medicine for minimally invasive treatment of osteomyelitis.
Previous studies have shown that oxidative stress plays an important role in regulating apoptosis of osteoblasts. 6, 7 It is very important that injectable nano-and/or micro-medicine promotes osteoblast proliferation under oxidative stress in the osteomyelitis microenvironment. Recently, L-lysine (Lys) has attracted extensive attention because of reducing inflammatory response. 8, 9 Currently, the development of nano-and/ or micro-spheres to form nano-or micro-medicine to promote osteoblast proliferation has been documented. [10] [11] [12] This strategy permits loading large quantities of drugs and smart stimulus response release mechanism. [13] [14] [15] [16] However, as far as amino acid
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chen et al is concerned, it has seldom been reported as injectable, pHresponsive micro-medicine. Herein, in this paper, we use a facile, one-pot method to construct injectable, pH sensitive, antibacterial, mineralized amino acid (Lys) yolk-shell structured microspheres (MSs) for potentially minimally invasive treatment of bone infection in situ. Hesperidin (Hesp), which has been reported to regulate the formation of CaCO 3 MSs in our former work, 17 was chosen as mineralization modifier. The protocol was altered from our previous work, 17 carbonate source changed from (NH 4 ) 2 CO 3 to NaHCO 3 . This change could provide an advantage when preparing yolk-shell structured products. The detailed steps are illustrated in Scheme 1. Firstly, our protocol included making an aqueous solution of Lys, Ca 2+ , and Hesp. Thus, Ca 2+ would be modified by the interactions with -OH (Hesp molecules) and nucleated into Ca-Hesp clusters. At the same time, Lys could be encapsulated into these clusters by the interaction between -NH 2 (Lys molecules) and Ca 2+ or -OH from Hesp molecules, resulting in Ca-Hesp-Lys complexes. Subsequently, NaHCO 3 solution was added into the aqueous solution drop by drop. Thus, these HCO 3 -were attracted by Ca 2+ from Ca-Hesp-Lys complexes, which provide sites for further nucleation. Due to the instability of HCO 3 -at higher temperatures, the out layer of the HCO 3 --Ca-Hesp-Lys complexes will be converted into CaCO 3 (as the shell of CaCO 3 MSs). The inner part of the complexes will be transported into the core of CaCO 3 MSs with diffusion of NH 3 (which can react with HCO 3 -to form CO 3
2-
). Finally, the yolk-shell structured Lys@CaCO 3 MSs were obtained after aging for a certain amount of time. Lys was encapsulated in the core, shell, and the void space. As illustrated in Scheme 2, Lys@ CaCO 3 MSs can improve the acidic environment of osteomyelitis due to the dissolution or fracture of CaCO 3 , while the released Lys can treat the damage caused by oxidative stress. Therefore, our strategy of mineralizing amino acid into yolk-shell MSs is facile, biocompatible, and pH sensitive MSs is highly promising for treating osteomyelitis.
Experiments Materials
Hesp and Lys (C 6 
Preparation of the lys@cacO 3 Mss
The yolk-shell structured Lys@CaCO 3 MSs were synthesized with a facile, one-pot method. Firstly, 0.4% (wt %) Hesp solution was prepared by alkaline aqueous solution (pH = 11.0, adjusted with ammonia and HCl). Then, a solution of CaCl 2 (5 mL, 0.5 mol/L), as-prepared Hesp solution (5 mL), and Lys (60 mg) were added into a beaker (150 mL), where 80 mL water was further added. Subsequently, NaHCO 3 (10 mL, 1 mol/L) was added. The mixture was stirred using vortex mixing (IKA, Vortex, Genius 3) to obtain a homogeneous solution. After that, the solution was heated to 65°C and kept for 20 min. The beaker and 100 mL ammonia (in another beaker) were placed in a closed desiccator for 24 h at room temperature. By NH 3 (diffused from ammonia) dissolving in the solution, the mineralization of the yolk-shell structured Lys@CaCO 3 MSs was initiated. The products were collected by centrifugation and then rinsed with deionized water several times. Finally, the obtained products were dried at 70°C for further analysis.
characterization
The morphologies of the obtained MSs were investigated by scanning electron microscopy (SEM; S4800, Hitachi Ltd., Tokyo, Japan) and transmission electron microscopy (TEM; JEM-1200EX; JEOL, Tokyo, Japan). The composition of CaCO 3 MSs was identified by using Fourier transform infrared spectroscopy (FTIR; Shimadzu, Kyoto, Japan) in the range of 4,000 to 400 cm -1 with the KBr disk method. The as-prepared CaCO 3 MSs were examined with power X-ray diffraction (XRD) analysis (Shimadzu) with Cu Kα radiation to obtain the crystallographic structure of the MSs.
The thermogravimetric (TG) data of the samples were assessed with a Netzsch STA 449CDSC/DTA-TG analyzer (Netzsch-Gerätebau GmbH, Selb, Germany) scanning from 30 to 600°C under an air atmosphere. The samples were weighed and introduced into aluminum pans. The pans were heated at a constant rate of 10°C/min in an nitrogen atmosphere with an empty aluminum pan as the reference probe. The sample mass was in the range of 8-10 mg. All samples were run in duplicate.
Investigation of lys release from lys@ cacO 3 
Mss
Acetate buffers (pH = 5.5) and PBS (pH = 7.4) were used for pH sensitivity investigation. Target samples were dispersed in the buffers and stirred for 5-10 minutes. The samples were centrifuged and the supernatant solutions were analyzed by an automatic potentiometric titrator (Excellence Titrator T9; Mettler-Toledo, LLC, Columbus, OH, USA). The release condition was set as 37°C, 1 atm pressure. Before confocal laser scanning microscopy (CLSM) images were taken, Lys@CaCO 3 MSs were stained green by FITC, cell nuclei were stained blue by Hoechst 33258, and the cytoskeleton was stained red by phalloidin. The detailed staining steps were in accordance with our previous work. [18] [19] [20] Gram-positive Staphylococcus aureus (S. aureus, ATCC 35696) was chosen. S. aureus was cultured at 37°C in a liquid Luria-Bertani medium at 300 rpm in a rotary shaker with and without Lys@CaCO 3 MSs for a certain amount of time. Then, the turbidity at 600 nm was measured by a Hitachi U-3010 spectrophotometer.
cell and antibacterial experiment
Western blot analysis and Pcr
In each group, after being incubated for a certain amount of time, osteoblast cells were lysed immediately in Laemmli buffer. Equal amounts of protein from each group were prepared using bicinchoninic acid and separated by sodium dodecyl sulfate/polyacrylamide gel electrophoresis. The proteins were transferred electrophoretically from the gels to PVDF membranes, which were then treated with anti-mouse Wnt3a and β-catenin antibodies overnight at 4°C. Subsequently, they were treated with a corresponding secondary antibody for 1 h. Immunoreactive proteins were revealed by using an enhanced chemiluminescence kit (Pierce Chemical, Rockford, IL, USA). Expression of GAPDH was used as the control. The autoradiograms were carried out on an Alpha Innotech Photo documentation System (Alpha Innotech, Hayward, CA, USA). The relative absorbance of the bands, representing the amount of protein expression, was analyzed using Quantity One software (Bio-Rad Laboratories Inc., Hercules, CA, USA).
After being incubated for a certain amount of time, the culture medium was used to determine the Wnt3a and β-catenin protein content using PCR, according to literature.
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Results and discussion
SEM image ( Figure 1A ) clearly shows the morphology of the obtained CaCO 3 crystals -MSs (2-5 μm in diameter). Figure 1B reveals the detailed morphology of a single Lys@ CaCO 3 MS having a rough surface. It is clear that the porous surface of such MS is composed of units of numerous small particles. TEM image in Figure 1C shows the yolk-shell structure of the obtained products with a thin shell and a condensed core. The magnified TEM image ( Figure 1D) shows the detailed structure of the shell. It is the aggregate of many spherical nanocrystals with an average size of approximately 30 nm in diameter. Figure 2 presents the FTIR spectra of CaCO 3 MSs without Lys, Lys and Lys@CaCO 3 MSs. Figure 2A shows CaCO 3 MSs with the characteristic absorption peaks of calcite located at 710 and 876 cm -1 and vaterite at 746 cm -1 . This suggests that the prepared CaCO 3 MSs have a mixed crystalline phase of calcite and vaterite. 17 It also indicates that the characteristic peak intensity of calcite is stronger than that of vaterite, which may suggest that calcite is the dominating crystalline phase. For Lys@CaCO 3 MSs, the broad absorption peak ranging from 896 to 823 cm -1 may be ascribed to the combined peaks from Lys and CaCO 3 . These data indicate that the obtained CaCO 3 MSs have been incorporated with Lys.
The XRD pattern result shown in Figure 3 further proved the polycrystalline property of the Lys@CaCO 3 Figure 4D ) was calculated by the following equation:
where m is the mass of Lys determined by potentiometric titration; M is the mass of CaCO 3 MSs used to load Lys in each group. Figure 4A -D revealed that the maximum DLC of the Lys@CaCO 3 MSs was 22.3 wt % when the 24.7 wt % Lys was added. Moreover, the drug loading efficiency (DLE) of the Lys@CaCO 3 MSs was 89.8%. TG curves of the assynthesized samples are shown in Figure 4E . After increasing the temperature, there was no significant weight loss for CaCO 3 MSs without Lys. However, a significant weight loss was observed for the obtained Lys@CaCO 3 MSs (the different amounts of Lys encapsulated), due to the combustion of Lys. TG analysis was consistent with previous experimental results ( Figure 4D ). It was found that the loading of Lys on Lys@CaCO 3 MSs increased with the increase of Lys dosage. The maximum DLC of the Lys@CaCO 3 MSs was studied based on the previously mentioned experimental results. Figure 5 presents the CLSM images of osteoblasts cultured under different conditions, which reveal the morphology change of osteoblasts. Figure 5A presents the image of normal osteoblasts cultured at pH = 7.4, which are full in shape (indicated by arrows) at the stage of normal proliferation and differentiation. However, Figure 5B shows the osteoblasts (indicated by arrows) which became flat or shorter at pH = 5.5 (simulating the mildly acidic microenvironment of osteomyelitis). This might be because the acidic environment is detrimental to the growth of osteoblasts. Osteoblasts became shorter or even died (indicated by arrows, Figure 5C ) when cultured under H 2 O 2 (80 μM, simulating oxidative stress conditions) at pH = 5.5. Figure 5D shows the osteoblasts which became relatively longer in the presence of Lys (0.8 mM) due to the anti-oxidation property of Lys. However, the osteoblasts were still flat, because the acidic environment still made osteoblasts grow abnormally. Osteoblasts' morphology returned to normal, full in shape ( Figure 5E ) by adding Lys@CaCO 3 MSs (containing 0.8 mM Lys). The possible reason being, when Lys was released from Lys@CaCO 3 MSs, the acidic environment was neutralized by the dissolution of CaCO 3 . Figure 5E also shows that some Lys@CaCO 3 MSs (stained green, indicated by arrows) were not completely dissolved.
From these changes in morphology results, it can be inferred that Lys@CaCO 3 MSs can help osteoblasts to resist acidic pH and H 2 O 2 . Figure 6 further indicates the effect of Lys@CaCO 3 MSs on the proliferation and differentiation of osteoblasts. Figure 6E (Figure 6M-P) . Figure 6O and P show that a small amount of Lys@CaCO 3 MSs (labeled by FITC, indicated by arrows) was not dissolved.
The release of Lys from Lys@CaCO 3 MSs (Figure 7A) , took place at different pH conditions (pH = 5.5 and pH = 7.4). The release amount was only 11.2% in PBS buffer (pH = 7.4) after dialysis for 6 h. When the release time increased from 6 h to 8 h, the release amount of Lys did not obviously increase. This indicated that most of the Lys was still stored in the Lys@CaCO 3 MSs, the measured small amount of Lys might be due to the surface-adsorbed ones. At pH = 5.5, 39.8% Lys was released within 1 h, and approximately 100% was released at about 8 h. These results demonstrate that the release of Lys from Lys@CaCO 3 MSs was strongly pH-dependent.
MTT method was used to further investigate the effect of Lys@CaCO 3 MSs on cell viability of osteoblasts at different pH conditions. Figure 7B shows the compared cell viability Figure 7C indicates that cell viability was obviously increased by increasing Lys concentration at pH = 7.4. However, when pH was changed from 7.4 to 5.5, cell viability increased slowly due to increasing Lys concentration. On the other hand, at pH = 7.4, increasing Lys@CaCO 3 MSs' concentration did not cause a significant difference in cell viability ( Figure 7D ). At pH = 5.5, the cell viability quickly increased up to 83.6% by increasing the concentration to 0.8 mM Lys (within Lys@CaCO 3 MSs). These results reveal an evidently acidity-enhanced release of Lys (to resist H 2 O 2 ) which increased cell proliferation because of the degradation of CaCO 3 .
To further consolidate our inference, we also evaluated cell viability of osteoblasts in the presence of free Lys and Lys@CaCO 3 MSs versus different culture times under the stimulation of H 2 O 2 (80 μM) at pH = 5.5. The results were shown in Figure 8 . There was a slightly decreased cell viability both in Lys-treated group and Lys@CaCO 3 MSs-treated group in the first 2 h. As acid has a strong lethality to cells, cell activity of osteoblasts continued to decline after 2 h in the pure Lys-treated group. For the Lys@ CaCO 3 MSs group, after 2 h, cell activity became increased because of the continuous release of Lys (to resist H beneficial for the growth of osteoblasts. The antibacterial property of Lys@CaCO 3 MSs is shown in Figure S1 , in the control group, there was an obvious increase of turbidity, indicative of S. aureus growth, while, compared to the control group, the turbidity decreased when introducing Lys@ CaCO 3 MSs into the culture system. From the inset image in Figure S1 , it is obvious that there was much more S. aureus in the control group than in the group cultured with Lys@ CaCO 3 MSs. This is probably due to the acidic microenvironment, caused by bacteria, being neutralized by CaCO 3 , and a mild alkaline environment (produced by the dissolved mineral from Lys@CaCO 3 MSs) is not conducive to bacterial growth. 18 The results in Figure S2 further indicate that Lys@ CaCO 3 has antibiotic activity to Escherichia coli (a classic Gram-negative bacteria), similar to that of S. aureus. These data further confirm that Lys@CaCO 3 MSs have a promising antibacterial function.
It is known that the Wnt/β-catenin pathway plays an important role in the differentiation and proliferation of osteoblasts under inflammatory conditions. 24, 25 Wnt proteins, such as Wnt1, Wnt2, Wnt3, Wnt3a, Wnt8, and Wnt8b, are significant as the starting factor for the Wnt/β-catenin pathway. 26 Moreover, β-catenin is a hub-type signaling molecule in the Wnt/β-catenin pathway, and its expression level is one of the common indicators for detecting the activation level of Wnt/β-catenin pathway. 27 Herein, we collected the gene expression of Wnt3a and β-catenin to explain the possible mechanism. Semi-quantitative RT-PCR data ( Figure 9) show that the expression of Wnt3a and β-catenin increased after Lys+H 2 O 2 treatment compared with H 2 O 2 treatment in an acidic environment. Due to the acidic environment being neutralized by dissolution of CaCO 3 MSs, with increased cell viability, the expression of Wnt3a and β-catenin increased significantly in the Lys@CaCO 3 MSs-treated group. In addition, Western blot assay ( Figure 10A ) and quantification analysis results ( Figure 10B and C Wnt/β-catenin pathway to promote the differentiation and proliferation of osteoblasts. At the same time, as the results in Figures S3 and S4 showed, Lys@CaCO 3 MSs can also increase the expression of OCN, OPN, and the activity of ALP after Lys+H 2 O 2 treatment compared with H 2 O 2 treatment in an acidic environment. Lys@CaCO 3 MSs reversed the oxidant-induced alterations in osteoblasts and may be a good option for treating osteomyelitis.
To develop micro-medicine for the treatment of osteomyelitis, there is still a long way to go. In addition to the data provided, we also give a future research plan here. We speculate that the addition of lysine can inhibit the differentiation of pre-osteoclasts into osteoclasts, but, unfortunately, it is difficult for us to obtain pre-osteoclasts in vitro. Therefore, this cannot be confirmed at present. Besides the limitation of osteoclasts, injectable properties of Lys@CaCO 3 MSs need to be confirmed by using an osteomyelitis animal model. The metabolism of MSs in vivo, including plasma concentrations, bone mass change, and blood calcium levels should be further investigated in the future. Further investigations about the expression of inflammatory factors and osteogenic related proteins and genes in vivo also need to be carried out.
Conclusion
In this work, we reported the preparation of Lys@CaCO 3 MSs by a facile bio-inspired mineralization method at room temperature. The obtained Lys@CaCO 3 MSs had a DLE of 89.8 wt % and DLC of 22.3 wt %. The CLSM images indicated that Lys@CaCO 3 MSs can reverse the oxidantinduced alterations in osteoblasts. Besides, because of their excellent pH-responsive drug release, and the dissolution or fracture by itself for improving the local acidic environment of osteomyelitis, our results demonstrate that the obtained Lys@CaCO 3 MSs can efficiently promote proliferation and differentiation of osteoblasts, and may be a good option for treating osteomyelitis.
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Supplementary materials
Figure S1 Time-dependent viability of Staphylococcus aureus (calculated by turbidity at 600 nm) co-cultured with and without lys@cacO 3 . Abbreviation: lys, l-lysine. 
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